A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-116 in Patients with Advanced Solid Tumors.

Taiho Pharmaceutical Co., Ltd.0 个研究点目标入组 61 人开始时间: 2014年2月17日最近更新: 2023年10月17日

研究概览

简要总结

Three oral dosing schedules, QD, QD x 5, and QOD of TAS-116 were evaluated in this first in human phase 1 study, and dosing regimens were identified for further development with promising preliminary clinical activities and safety profiles.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•Signed, written informed consent.
•- Histologically or cytologically confirmed solid tumor.
•- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

排除标准

•- Investigational drug therapy within 21 days prior to enrollment.
•- Radiotherapy within 21 days prior to enrollment.
•- Received extensive prior radiotherapy on more than 30% of bone marrow.
•- Females who are pregnant or breastfeeding.
•- Serious complications.

研究者

发起方

Taiho Pharmaceutical Co., Ltd.

相似试验

已完成

1 期

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

NCT02457793Genentech, Inc.24

招募中

1 期

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast CancerAdvanced or Metastatic Breast Cancer

NCT05187832Kind Pharmaceuticals LLC61

已完成

1 期

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid TumorsAdvanced Solid TumorsRecurrent or Refractory MedulloblastomaLocally Advanced or Metastatic Basal Cell Carcinoma

NCT01106508Novartis Pharmaceuticals57

招募中

1 期

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic MalignanciesNon Small Cell Lung CancerAdvanced Solid TumorHematologic Malignancy

NCT06484816Shenzhen TargetRx, Inc.90

Unknown

1 期

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Advanced Solid Tumors (Part A/B/C/D)Non-small Cell Lung Cancer (Part E)Melanoma (Part E)Squamous Cell Cancer of the Head and Neck (Part E)Triple Negative Breast Cancer (Part F)Adrenocortical Carcinoma (Part G)Mesothelioma (Part G)High-circulating Myeloid-derived Suppressor Cells (Part H)

NCT02637531Infinity Pharmaceuticals, Inc.219